Suven Life Sciences Limited's Board of Directors has formally approved the conversion of warrants into equity shares, completing a significant capital raising exercise. The board meeting held on March 6, 2026, resulted in the allotment of 3,17,68,764 equity shares to a promoter group entity, strengthening the company's financial position.

Board Meeting Outcome

The Board of Directors meeting, which commenced at 11:00 AM IST and concluded at 11:20 AM IST on March 6, 2026, approved the conversion of fully paid warrants into equity shares. The conversion was executed in accordance with SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018.

Allotment Details

The company has allotted 3,17,68,764 equity shares of ₹1 each to JASTI PROPERTY AND EQUITY HOLDINGS PRIVATE LIMITED in its capacity as sole trustee of Jasti Family Trust. This promoter group entity has provided 100% consideration amount aggregating to ₹425,70,14,376 in compliance with regulatory requirements.

Capital Structure Impact

The warrant conversion has resulted in a significant expansion of the company's equity base. The paid-up equity share capital has increased substantially following the allotment.

Shareholding Pattern Changes

Following the preferential allotment, Jasti Property and Equity Holdings Private Limited's shareholding has increased significantly. The regulatory disclosure filed on March 9, 2026, reveals the updated shareholding structure of the promoter group.

Regulatory Compliance

The allotment was conducted as a preferential issue in accordance with Chapter V of the SEBI (ICDR) Regulations, 2018. The company has fulfilled all disclosure requirements pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ensuring complete transparency in the process. Additionally, Jasti Property and Equity Holdings Private Limited has filed the mandatory disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, confirming the acquisition details to both BSE and NSE.

This successful warrant conversion demonstrates strong promoter confidence and provides Suven Life Sciences with enhanced financial resources to pursue its strategic objectives in the pharmaceutical sector.

Suven Life Sciences Limited has issued a formal clarification to BSE Limited addressing recent price movements in its stock. The communication, dated February 6, 2026, was submitted in response to BSE's surveillance inquiry regarding unusual price activity.

Company's Response to BSE Surveillance

The pharmaceutical company clarified its position through a detailed response to BSE's surveillance department. The clarification was prompted by BSE's inquiry reference L/SURV/ONL/PV/AJ/ 2025-2026 / 3355 dated February 5, 2026.

Regulatory Compliance Statement

Suven Life Sciences emphasized its commitment to regulatory compliance, stating that the company has been consistently notifying stock exchanges of all material events and information falling under Regulation 30 of SEBI (LODR) Regulations, 2015. The company maintained that it follows proper disclosure protocols for all significant developments.

The management confirmed that no material announcements or events are currently pending notification to stock exchanges under SEBI regulations that could influence the stock's price or volume behavior.

Market Speculation Attribution

The company attributed recent price and volume movements to market speculation rather than any undisclosed material information. Suven Life Sciences stated it has no additional comments regarding the recent market developments affecting its stock performance.

The clarification has been made available to the general public through dissemination on BSE's website and the company's official website, ensuring transparency in communication with stakeholders.